General Information |
|
Product |
PDE4B2 Positive Control |
Description |
Western Blot Positive Control cAMP-specific 3',5'-cyclic phosphodiesterase 4B isoform 2 |
Verified Applications |
WB |
Immunogen |
Purified Protein |
Accession # |
NCBI: NP_001032416.1 |
|
|
Quantity |
5 Applications |
Volume |
Inquire |
Form |
Western Blot Positive Control |
Storage |
-20⁰C for long term storage |
|
|
Western Blot |
1:750 |
|
|
Uniprot # |
|
Overview |
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. |
Molecular Function |
Hydrolase, 3',5'-cyclic-AMP phosphodiesterase activity, cAMP binding |
Expression |
Expressed in brain, heart, lung and skeletal muscle. |
Alternative Nomenclature |
5''-cyclic phosphodiesterase 4B antibody cAMP-specific 3'' antibody DPDE4 antibody dunce-like phosphodiesterase E4 antibody MGC126529 antibody PDE 4B antibody PDE IVB antibody PDE32 antibody PDE4B5 antibody PDEIVB antibody Phosphodiesterase 4B2 antibody |
Protein information supplied by UniProt
Fabgennix PDE4B2 Antibody has been used in 2 Publications |
|
Amanda, G. Vang, et al. "Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac." Biochemical Journal 456.3 (2013): 463-473.
|
Western Blot; Mouse |
Hajjhussein, Hassan et al. “Changes in NMDA Receptor-Induced Cyclic Nucleotide Synthesis Regulate the Age-Dependent Increase in PDE4A Expression in Primary Cortical Cultures.” Brain research 1149 (2007): 58–68. PMC2720317
|
Immunoprecipitation, Western Blot; Human |
Publishing research using PD4B2-251AP? Please let us know, we can cite the reference in this datasheet.
Product | Note | Status | Price | |
---|---|---|---|---|
|
PD4B2-251AP | |||
|
PD4B2-FITC | |||
|
P-PD4B2 | |||
|
PD4B2-BIOTIN | |||
Display accessory details |
Select your currency:
(c) FabGennix International Inc.